In-Licensing: In-licensing of U.S. FDA-approved ANDA products for commercialization across domestic retail, hospital, and federal channels.

Out-Licensing: Out-licensing of our established U.S. portfolio to international partners for global territory expansion.

Asset Buyouts: Direct acquisition of approved, mature, or divested ANDA products.

Rapid Re-Launch: Seamless transfer of NDAs/ANDAs into our U.S. network for quick commercial scaling.

Co-Owned Execution: Shared commercial structures combining our market access with partner IP and operational capacity.

Aligned Growth: Collaborative revenue-sharing models focused on targeted U.S. channel penetration.

Launch Readiness: Late-stage commercial alignment and registration setup for market deployment.

Commercial Alignment: Operational and capital partnering to ensure efficient, immediate channel adoption.